{"denomUnitsSelected":"Participants","description":"Percentage of patients experiencing grade 3 or higher adverse events will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All patients who receive at least one dose of protocol therapy will be considered in the evaluation of toxicity.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 2 years from study entry","title":"Percentage of Patients Experiencing Grade 3 or Higher Adverse Events","type":"SECONDARY"}